Accumulation of Methotrexate Polyglutamates, Ploidy and Trisomies of Both Chromosomes 4 and 10 in Lymphoblasts from Children with B-Progenitor Cell Acute Lymphoblastic Leukemia: a Pediatric Oncology Group Study

References

• Niemeyer C.M., Hitchcock-Bryan S., Sallan S.E. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Sem. Oncol. 1985; 12: 122–130
   PubMed Web of Science ®Google Scholar
• Pinkel D. Curing children of leukemia. Cancer 1987; 59: 1683–1691
   PubMed Web of Science ®Google Scholar
• Rivera G.K., Mauer A.M. Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification C N S leukemia, and prognostic factors. Sem. Hematol 1987; 24: 12–26
   PubMed Web of Science ®Google Scholar
• Craft A.W., Rankin A., Aherae W. Methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Treatment Report 1981; 65: 77–81
   PubMedGoogle Scholar
• Balis F.M., Savitch J.L., Bleyer W.A. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983; 43: 2342–2345
   PubMed Web of Science ®Google Scholar
• Evans W.E., Crom W.R., Abromowitch M., Dodge R., Look A.T., Bowman W.P., George S.L., Pui C-H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl. J. Med. 1986; 314: 471–477
   PubMed Web of Science ®Google Scholar
• Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitamins Hormones 1989; 45: 263–335
   PubMed Web of Science ®Google Scholar
• Rosenblatt D.S., Whitehead V.M., Vera N., Pottier A., Dupont M., Vuchich M-J. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured cells. Mol Pharmacol 1978; 14: 1143–1147
   PubMed Web of Science ®Google Scholar
• Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol. Pharmacol 1980; 17: 105–110
   PubMed Web of Science ®Google Scholar
• Fry D.W., Yalowich J.C., Goldman I.D. Rapid formation of polygammaglutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high-pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J. Biol. Chem. 1982; 257: 1890–1896
   PubMed Web of Science ®Google Scholar
• Jolivet J., Chabner B.A. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells: selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J. Clin. Invest. 1983; 72: 773–778
   PubMed Web of Science ®Google Scholar
• Whitehead V.M. Synthesis of methotrexate poly glutamates in murine L1210 leukemia cells. Cancer Res. 1977; 37: 408–412
   PubMed Web of Science ®Google Scholar
• Jacobs S.A., Adamson R.H., Chabner B.A., Derr C.J., Johns D.G. Stoichiometric inhibition of mammalian dihydrofolate reductase by the γ-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N10-methylpteroyl-glutamyl-γ-glutamate. Biochem. Biophys. Res. Commun. 1975; 63: 692–698
   PubMed Web of Science ®Google Scholar
• Kisliuk R.L., Gaumont Y., Baugh C.M., Galivan J.M., Maley G.F., Maley F. Inhibition of thymidylate synthetase by poly-γ-glutamyl derivatives of folic acid and methotrexate. Chemistry and Biology of Pteridines, R.L. Kisliuk, G.M. Brown. Elsevier/North Holland, New York, N.Y 1979; 431–435
   Google Scholar
• Allegra C.J., Chabner B.A., Drake J.C., Lutz R., Rod-Bard D. Enhanced inhibition of thymidylate synthetase by methotrexate polyglutamates. J. Biol. Chem. 1985; 260: 9720–9726
   PubMed Web of Science ®Google Scholar
• Allegra C.J., Drake J.C., Jolivet J., Chabner B.A. Inhibition of phosphoribosyl-aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA 1985; 82: 4881–4885
   PubMed Web of Science ®Google Scholar
• Fischer G.A. Defective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells. Biochem. Pharmacol. 1962; 11: 1233–1234
   PubMed Web of Science ®Google Scholar
• Trippett T., Schlemmer S., Elisseyeff Y., Goker E., Wachter M., Steinherz P., Tan C., Berman E., Wright J.E., Rosowsky A., Schweitzer B., Bertino J.R. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood 1992; 80: 1158–1162
   PubMed Web of Science ®Google Scholar
• Alt F.W., Kellems R.E., Bertino J.R., Schimke R.T. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol Chem. 1978; 253: 1357–1370
   PubMed Web of Science ®Google Scholar
• Goldie J.H., Krystal G., Hartley D., Gudauskas G., Dedhar S. A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. Eur. J. Cancer 1980; 16: 1539–1546
   PubMed Web of Science ®Google Scholar
• Flintoff W.F., Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochem. 1980; 19: 4321–4327
   PubMed Web of Science ®Google Scholar
• Horns R., Dower W.J., Schimke R.T. Gene amplification in a leukemic patient treated with methotrexate. J. Clin. Oncol. 1984; 2: 2–8
   PubMed Web of Science ®Google Scholar
• Carman M.D., Schornagel J.H., Rivest R.S., Srimatkandada S., Portlock C.S., Bertino J.R. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J. Clin. Oncol. 1984; 2: 16–21
   PubMed Web of Science ®Google Scholar
• Cowan K.H., Jolivet J. A methotrexate-resistant human breast cancer cell line with multiple defects including diminished formation of methotrexate polyglutamates. J. Biol. Chem. 1984; 259: 10793–10800
   PubMed Web of Science ®Google Scholar
• Pizzorno G., Mini E., Coronello M., McGuire J.J., Moroson B.A., Cashmare A.R., Dreyer R.N., Lin J.T., Mazzei T., Periti P., Bertino J.R. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res. 1988; 48: 2149–2155
   PubMed Web of Science ®Google Scholar
• Whitehead V.M., Rosenblatt D.S., Vuchich M-J., Beau-Lieu D. Methotrexate polyglutamate synthesis in lymphoblasts from children with acute lymphoblastic leukemia. Dev. Pharmacol. Ther. 1987; 10: 443–448
   PubMedGoogle Scholar
• Koizumi S., Curt G.A., Fine R.L., Griffin J.D., Chabner B.A. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J. Clin. Invest. 1985; 75: 1008–1014
   PubMed Web of Science ®Google Scholar
• Whitehead V.M., Rosenblatt D.S., Vuchich M-J., Shuster J.J., Witte A., Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 1990; 76: 44–49
   PubMed Web of Science ®Google Scholar
• Whitehead V.M., Vuchich M-J., Lauer S.J., Mahoney D., Carroll A.J., Shuster J.J., Esseltine D.W., Payment C., Look A.T., Akabutu J., Bowen T., Taylor L.D., Camitta B., Pullen D. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (> 50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 1992; 80: 1316–1323
   PubMed Web of Science ®Google Scholar
• Synold T.W., Relling M.V., Boyett J.M., Rivera G.K., Sandlund J.T., Mahmoud H., Crist W.M., Pui C-H., Evans W.E. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 1994; 94: 1996–2001
   PubMed Web of Science ®Google Scholar
• Masson E., Relling M.V, Synold T.W, Liu Q., Schuetz J.D, Sandlund J.T, Pui C-H., Evans W.E. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J. Clin. Invest. 1996; 97: 73–80
   PubMed Web of Science ®Google Scholar
• Trueworthy R., Shuster J., Look T., Crist W., Borowitz M., Carroll A., Frankel L., Harris M., Wagner H., Haggard M., Mosijczuk A., Pullen J., Steuber P., Land V. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J. Clin. Oncol. 1992; 10: 606–613
   PubMed Web of Science ®Google Scholar
• Harris M.B., Shuster J.J., Carroll A., Look A.T., Borowitz M.J., Crist W.M., Nitschke R., Pullen J., Steuber C.P., Land V.J. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood 1992; 79: 3316–3324
   PubMed Web of Science ®Google Scholar
• Crist W.M., Carroll A.J., Shuster J.J., Behm F.G., Whitehead M., Vietti T.J., Look A.T., Mahoney D., Ragab A., Pullen D.J., Land V.J. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood 1990; 76: 117–122
   PubMed Web of Science ®Google Scholar
• Look A.T., Melvin S.L., Williams S.L., Brodeur G.M., Dahl G.V., Kalwinsky D.K., Murphy S.B., Mauer A.M. Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood 1982; 60: 959–967
   PubMed Web of Science ®Google Scholar
• Lehmann E.L. Nonparametrics: Statistical methods based on ranks. Holden-Day, San Francisco, C A. 1975, Chapter 7
   Google Scholar
• Lehmann E.L. Nonparametrics: Statistical methods based on ranks. Holden-Day, San Francisco, CA 1975, Chapter 2
   Google Scholar
• Jones C., Kao F-T, Taylor RT. Chromosomal assignment of the gene for folylpolyglutamate synthetase to human chromosome 9. Cytogenet. Cell Genet. 1980; 28: 181–194
   PubMedGoogle Scholar
• Manabe A., Coustan-Smith E., Behm F.G, Raimondi S.C, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370–2377
   PubMed Web of Science ®Google Scholar
• Lenz H-J., Danenberg K., Schneiders B., Goeker E., Peters G.J., Garrow T., Shane B., Bertino J.R., Danenberg P.V. Quantitative analysis of folylpolyglutamate synthetase expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemic patients. Oncol. Res. 1994; 6: 329–335
   PubMed Web of Science ®Google Scholar
• Barredo J.C., Synold T.W., Laver J., Relling M.V., Pui C-H., Priest D.G., Evans W.E. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994; 84: 564–569
   PubMed Web of Science ®Google Scholar
• Prasad P.D., Ramamoorthy S., Leibach F.H., Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995; 206: 681–687
   PubMed Web of Science ®Google Scholar
• Williams F.M., Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol Chem 1995; 270: 2987–2992
   Web of Science ®Google Scholar
• Wong S.C., Proefke S.A., Bhushan A., Matherly L.H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J. Biol. Chem. 1995; 270: 17468–75
   PubMed Web of Science ®Google Scholar
• Moscow J.A., Gong M., He R., Sgagias M.K., Dixon K.H., Anzick S.L., Meltzer P.S., Cowan K.H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 1995; 55: 3790–3794
   PubMed Web of Science ®Google Scholar
• Yao R., Schneider E., Ryan T.J., Galivan J. Human γ-glutamyl hydrolase: Cloning and characterization of the enzyme expressed in vitro. Proc. Natl. Acad. Sci. (USA) 1996; 93: 1904–1908
   Google Scholar
• Garre M.L., Relling M.V., Kalwinsky D., Dodge R., Crom W.R., Abromowitch M., Pui C-H., Evans W.E. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J. Pediatr 1987; 111: 606–612
   PubMed Web of Science ®Google Scholar
• Whitehead V.M., Vuchich M.-J., Cooley L.D., Lauer S.J., Mahoney D., Shuster J.J., Payment C., Bernstein M.L., Akabutu J.J., Bowen T., Kamen B.A., Watson M.S., Look A.T., Pullen D.J., Camitta B. Translocations involving chromosome 12p11-13, methotrexate metabolism and outcome in childhood B-lineage acute lymphoblastic leukemia (ALL). Clin. Cancer Res. 1998; 4: 183–188
   PubMed Web of Science ®Google Scholar
• Raimondi S.C., Pui C-H., Hancock M.L., Behm F.G., Filatov L., Rivera G.K. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 213–224
   PubMed Web of Science ®Google Scholar
• Brodeur G.M., Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. [Review]. Am. J. Ped. Hemat. Oncol. 1992; 14: 111–116
   PubMedGoogle Scholar
• Thompson M.W., McLnnes R.R., Willard H.F. Genetics in Medicine, 5th Edition. W.B. Saunders Co, Philadelphia 1991; 201–229
   Google Scholar
• Onodera N., McCabe N.R., Rubin C.M. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood 1992; 80: 203–208
   PubMed Web of Science ®Google Scholar
• Kaspers G.J.L., Smets L.A., Pieters R., Van Zantwijk C.H., Van Wering E.R., Veerman A.J.P. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751–756
   PubMed Web of Science ®Google Scholar